Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2

15 Mar 2021

Abstract excerpt

Preexisting cross-reactivity to SARS-CoV-2 occurs in the absence of prior viral exposure. However, this has been difficult to quantify at the population level due to a lack of reliably defined seroreactivity thresholds. Using an orthogonal antibody testing approach, we estimated that about 0.6% of nontriaged adults from the greater Vancouver, Canada, area between May 17 and June 19, 2020, showed clear evidence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33720905
DOI: 10.1172/jci.insight.146316

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2PMID 33720905Read ↗

Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronavirusesSemantic proximity Read ↗

Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individualsSemantic proximity Read ↗

Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variantSemantic proximity Read ↗

Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with an endemic human CoVSemantic proximity Read ↗

Going beyond clinical routine in SARS-CoV-2 antibody testing - A multiplex corona virus antibody test for the evaluation of cross-reactivity to endemic coronavirus antigensSemantic proximity Read ↗

Seroprevalence, seroconversion, and seroreversion of infection-induced SARS-CoV-2 antibodies among a cohort of children and adolescents in Montreal, CanadaSemantic proximity Read ↗

Cross-Reactivity of SARS-CoV Structural Protein Antibodies Against SARS-CoV-2Semantic proximity Read ↗

Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native and B.1.351 SARS-CoV-2 spike proteinsSemantic proximity Read ↗

A comprehensive antigen production and characterization study for easy-to-implement, highly specific and quantitative SARS-CoV-2 antibody assaysSemantic proximity Read ↗

Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccinationSemantic proximity Read ↗

Antibody response to SARS-CoV-2 infection in humans: a systematic reviewSemantic proximity Read ↗

A Longitudinal Seroepidemiology Study to Evaluate Antibody Response to SARS-CoV-2 Virus and Vaccination in Children in Calgary, Canada from July 2020 to April 2022Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.